RIB Trans Study
Research type
Research Study
Full title
Biomarker analysis to predict response of metastatic bone pain in prostate cancer.
IRAS ID
238701
Contact name
Peter J Hoskin
Contact email
Sponsor organisation
University College London
Duration of Study in the UK
1 years, 1 months, 1 days
Research summary
Summary of Research
Using commercially available urine tests for markers of bone turnover the optimal treatment for metastatic bone pain in patients with prostate cancer will be defined. Two distinct strategies will be investigated: single dose radiotherapy which is considered the 'gold standard' and a single intravenous infusion of a bisphosphonate drug ibandronate based on the results of our RIB trial.
Also we will explore the mechanism of bone pain relief using these agents. Ibandronate acts solely on osteoclast inhibition whilst radiotherapy has effects on other host tissues including nerves and stromal cells and a direct action on cancer cells.Summary of Results
The Radiotherapy or Ibandronate (RIB) study was a large randomised trial in men with metastatic bone pain from prostate cancer. They were randomised to receive either standard radiotherapy or a single dose infusion of a bisphosphonate drug called ibandronate. The RIB Trans study was undertaken on urine samples collected from approximately 350 patients who participated in the RIB trial, at 3 timepoints during the trial: Before treatment, 4 weeks and 12 weeks after treatment (either radiotherapy or ibandronate). The samples were analysed for the presence of two potential markers of bone pain in the three timed samples. It was hoped that this would reveal a prediction of pain reduction response to either radiotherapy or ibandronate treatment. The results showed no overall difference in the percentage of patients who reported pain relief between the two treatments.
REC name
London - Queen Square Research Ethics Committee
REC reference
18/LO/0290
Date of REC Opinion
16 Feb 2018
REC opinion
Favourable Opinion